X4 Pharmaceuticals Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the first quarter 2026, X4 Pharmaceuticals Inc's inventory turnover ratio sequentially decreased to 0.4 in the first quarter 2026, unsurprisingly, as the X4 Pharmaceuticals Inc markets continue to deteriorate, and XFOR's faces growing challenges to bring down its inventories. X4 Pharmaceuticals Inc's average inventory processing period in the Mar 31 2026 quarter, has increased to 913 days, from 235 days, in the Dec 31 2025 quarter.

Within Healthcare sector 355 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1386 in the fourth quarter 2025, to 1787.

XFOR Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is X4 Pharmaceuticals Inc Market Share?

What is Inventory Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Inventory Turnover▼

None ▼

Inventory Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

XFOR Inventory Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Inventory Growth	50.11 %	59 %	66.87 %	281.47 %	-
Y / Y Cost of Sales Growth	-87.32 %	20.53 %	54.63 %	21.64 %	-
Inventory Turnover Ratio (TTM)	0.4	1.55	1.73	1.93	2.4
XFOR's Total Ranking	# 1787	# 1386	# 1033	# 1202	# 1038
Average inventory processing period	911	235	211	189	152
Seq. Inventory Growth	3.53 %	9.78 %	28.71 %	2.62 %	9.66 %
Seq. Cost of Sales Growth	64.29 %	3.7 %	7.67 %	-93.09 %	1461.59 %

Inventory Turnover Ratio Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 27
Healthcare Sector	# 356
Overall Market	# 1787

Inventory Turnover Ratio Statistics
High	Average	Low
2.4	1.6	0.4
(Mar 31 2025)		(Mar 31 2026)

XFOR Company Profile >> Back to XFOR Efficiency Comparisons >> Compare XFOR Inventory Turnover Ratio to its Competitors

Financial Statements
X4 Pharmaceuticals Inc's Inventories	$ 5 Millions	Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Cost of Revenues TTM	$ 2 Millions	Visit XFOR's Income Statement
What are XFOR's Sales?		Visit XFOR's Sales by Segment

Other Inventory Turnover Ratios
X4 Pharmaceuticals Inc's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Biotechnology & Pharmaceuticals Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
XFOR's Inventory Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for XFOR's Competitors
Inventory Turnover Ratio for XFOR's Suppliers
Inventory Turnover Ratio for XFOR's Customers

You may also want to know
XFOR's Sales Growth Rates	XFOR's Pe Price to earnings ratio	XFOR's Receivables Turnover Ratio	XFOR's Stock Quote
XFOR's Net Income Growth Rates	XFOR's Ps Price to Sales ratio	XFOR's Sales per Employee	XFOR's Asset Turnover Ratio
XFOR's Net Margin	XFOR's Pb Price to Book ratio	XFOR's Financial Strength Ratios	XFOR's Dividend Payout Ratio

Companies with similar Inventory Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Inventory Turnover Ratio	Cost of revenues at quarter ending Mar 31 2026	Inventories at quarter ending Mar 31 2026
Ionis Pharmaceuticals Inc	0.97	$ 8.597 Millions	$ 9 Millions
Rhythm Pharmaceuticals Inc	0.96	$ 23.001 Millions	$ 24 Millions
Eli Lilly And Company	0.96	$ 12,404.800 Millions	$ 12,867 Millions
Rxsight Inc	0.96	$ 29.000 Millions	$ 30 Millions
Adma Biologics Inc	0.96	$ 195.347 Millions	$ 204 Millions
Protalix Biotherapeutics inc	0.93	$ 22.940 Millions	$ 25 Millions
Alkermes Plc	0.91	$ 208.838 Millions	$ 229 Millions
Emergent Biosolutions Inc	0.91	$ 309.700 Millions	$ 341 Millions
Inspire Medical Systems inc	0.90	$ 130.000 Millions	$ 144 Millions
Seer Inc	0.89	$ 7.000 Millions	$ 8 Millions
Abeona Therapeutics Inc	0.89	$ 4.228 Millions	$ 5 Millions
Liquidia Corporation	0.88	$ 18.386 Millions	$ 21 Millions
Humacyte Inc	0.88	$ 11.593 Millions	$ 13 Millions
Neurocrine Biosciences Inc	0.87	$ 56.700 Millions	$ 65 Millions
Tg Therapeutics Inc	0.85	$ 118.683 Millions	$ 139 Millions
Butterfly Network Inc	0.83	$ 52.000 Millions	$ 63 Millions
Maxcyte inc	0.82	$ 6.294 Millions	$ 8 Millions
Bioxcel Therapeutics Inc	0.79	$ 0.433 Millions	$ 1 Millions
Establishment Labs Holdings Inc	0.77	$ 68.000 Millions	$ 89 Millions
Sintx Technologies Inc	0.72	$ 0.547 Millions	$ 1 Millions
Rafael Holdings Inc	0.72	$ 0.201 Millions	$ 0 Millions
Immunocore Holdings Plc	0.72	$ 4.690 Millions	$ 7 Millions
Igc Pharma Inc	0.70	$ 0.704 Millions	$ 1 Millions
Siga Technologies Inc	0.69	$ 32.487 Millions	$ 47 Millions
Milestone Scientific Inc	0.67	$ 2.579 Millions	$ 4 Millions
Picard Medical Inc	0.67	$ 4.731 Millions	$ 7 Millions
Xeris Biopharma Holdings Inc	0.64	$ 44.415 Millions	$ 69 Millions
Orchestra Biomed Holdings Inc	0.63	$ 0.178 Millions	$ 0 Millions
Envoy Medical Inc	0.61	$ 0.961 Millions	$ 2 Millions
Organogenesis Holdings Inc	0.60	$ 19.764 Millions	$ 33 Millions

Date modified: 2026-09-05T07:07:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.